Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) An antineoplastic composition comprising an antineoplastic-effective amount of a methylol transfer agent (MTA) in combination with a biodegradable adhesive capable of adhering to tissue of a living subject.

2. (Original) The composition of claim 1 wherein said MTA is taurolidine, taurultam or a mixture thereof, said composition initially is in a fluid or semi-fluid state with said MTA at a concentration within a range of about 0.5-80% by weight, and after said adhering to said tissue, said adhesive increases in viscosity or at least partially solidifies while adhering to said tissue.

3. (Original) The composition of claim 1 wherein said composition initially is in a liquid, semi-liquid or suspension state, said MTA is taurolidine, taurultam or a mixture thereof, and is at a concentration within a range of about 0.1-160mg/ml, and after said adhering to said tissue, said adhesive increases in viscosity or at least partially solidifies while adhering to said tissue.

4. (Original) The composition of claim 3 wherein said adhesive comprises a fibrin sealant matrix.

5. (Original) The composition of claim 4 wherein said concentration is about 20-100mg/ml.

6. (Original) The composition of claim 5 wherein said concentration is about 50-80mg/ml.

7. (Withdrawn) A method of treatment for preventing or inhibiting growth of cancer cells, comprising applying the antineoplastic composition of claim 1 to tissue of a living subject in need of said treatment.

8. (Withdrawn) The method of claim 7 wherein said MTA is taurolidine, taurultam or a mixture thereof, said composition is applied to said tissue in a fluid or semi-fluid state with said MTA at a concentration within a range of about 0.5-80% by weight, and after said composition is applied, said adhesive increases in viscosity or at least partially solidifies while adhering to said tissue.

9. (Withdrawn) The method of claim 7 wherein said state is a liquid, semi-liquid or suspension state, said MTA is taurolidine, taurultam or a mixture thereof, and is at a concentration within a range of about 0.1-160mg/ml, and after said composition is applied, said adhesive increases in viscosity or at least partially solidifies while adhering to said tissue.

10. (Withdrawn) The method of claim 9 wherein said adhesive comprises a fibrin sealant matrix.

11. (Withdrawn) The method of claim 10 wherein said concentration is about 20-100mg/ml.

12. (Withdrawn) The method of claim 5 wherein said concentration is about 50-80mg/ml.

13. (Withdrawn) The method of claim 7 wherein prior to said applying, a tumor is removed from an area of said tissue.

14. (Withdrawn) The method of claim 13 wherein said composition is applied to said area in a layer.

15. (Withdrawn) The method of claim 14 wherein said layer has a thickness of about 0.1-10mm.

16. (Withdrawn) The method of claim 15 wherein said layer has a thickness of about 1-5mm.

17. (Withdrawn) The method of claim 16 wherein said layer has a thickness of about 1.5-2.5mm.

18. (Withdrawn) The method of claim 14 wherein said layer is applied by spraying said composition onto said area.

19. (Withdrawn) The method of claim 14 wherein, after application of said layer, said layer is covered and sealed with a sealing second layer which does not contain said MTA.

20. (Previously presented) The composition of claim 1 wherein said MTA is taurolidine, taurultam or a mixture thereof.

21. (Withdrawn) The method of claim 7 wherein said MTA is taurolidine, taurultam or a mixture thereof.

22. (Withdrawn) The method of claim 7 further comprising intravenous administration of said MTA to said subject.

23. (Withdrawn) The method of claim 22 wherein said MTA is taurolidine, taurultam or a mixture thereof.

24. (Previously presented) A system for preventing or inhibiting growth of cancer cells in a subject, comprising the antineoplastic composition of claim 1, in combination with an intravenously administrable MTA for intravenous administration to said subject.

25. (Previously presented) The system of claim 24 wherein said MTA is taurolidine, taurultam or a mixture thereof.